阿摩線上測驗
30.下列何者為selective endothelin receptor antagonist，能顯著降低血壓？
(A)Clevidipine
(B)Darusentan
(C)Nebivolol
(D)Aliskiren
統計： A(93), B(1713), C(72), D(428), E(0) #408134
詳解 (共 7 筆)
(B)Darusentan→endothelin receptor antagonist
(C)Nebivolol→β1 blocker
(D)Aliskiren→renin inhibitors
Darusentan is an endothelin receptor antagonist is developing darusentan for the potential treatment of uncontrolled hypertension. 能顯著降低血壓,用於治療肺動脈高血壓
內皮素受體拮抗劑: Darusentan ,sitaxentan ,ambrisentan ,bosentan Drug Classes → Cardiovascular Agents → Agents For Pulmonary Hypertension
selective endothelin receptor antagonist：
-sentan(Darusentan ,sitaxentan ,ambrisentan ,bosentan)
endothelin - Darusentan
臨床試驗顯示ET antagonist 對HFrEF 沒效，darusentan 就是其中一個失敗的案例
The effect of selective ET-A receptor blockade was evaluated in the EARTH trial, in which 642 patients with HF (79 percent NYHA class III) and an ejection fraction less than or equal to 35 percent were randomly assigned to one of five doses of darusentan or placebo. At 24 weeks, the primary end point (magnetic resonance measured left ventricular end systolic volume) did not change significantly with any dose of darusentan compared to placebo. There were also no significant changes in symptoms, neurohormone concentrations, or clinical outcomes with darusentan. The withdrawal rate due to an adverse effect was 10.5 percent in the darusentan group versus 2.7 percent in placebo-treated patients.
UpToDate Role of endothelin in heart failure with reduced ejection fraction